Schrodinger

koto_feja Bristol-Myers Squibb (New York Stock Exchange: BMI) Rights to its preclinical cancer drug candidate, an SOS1 inhibitor, have been returned to Schrödinger (Nasdaq:SDGR). Schrödinger noted that he had submitted a candidate…